MinorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Histamine analogue, antivertigo agent
Updated · Methodology
Mechanism
In the body, acetylsalicylic acid is converted to salicylic acid, which is metabolised mainly in the liver, and the kidneys excrete the metabolites (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After absorption, betahistine is rapidly and almost completely metabolised to inactive 2-pyridylacetic acid. About 85% of the dose is recovered in the urine, and less than 5% of the drug binds to plasma proteins (betahistine SmPC, AEMPS). The betahistine documents name two groups. Monoamine oxidase inhibitors (MAOIs) inhibited its metabolism in vitro, and betahistine is combined with them with caution. With antihistamines, the efficacy of one of the two drugs may in theory change (betahistine SmPC, AEMPS). Acetylsalicylic acid belongs to neither group, and neither the Spanish nor the US documents for acetylsalicylic acid mention betahistine or histamine analogues (SmPCs of both drugs, AEMPS; aspirin label, US Food and Drug Administration, FDA). The documents say nothing about either drug changing the levels of the other. Based on in vitro results, betahistine is not expected to inhibit cytochrome P450 enzymes in vivo (betahistine SmPC, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. Acetylsalicylic acid can cause bronchospasm and asthma attacks. Treatment with non-steroidal anti-inflammatory drugs, which include acetylsalicylic acid, is associated with bleeding, ulceration and perforation of the upper gastrointestinal tract. These can occur at any time during treatment without previous symptoms (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Betahistine commonly causes nausea, dyspepsia and headache. After marketing, mild gastric complaints such as vomiting, abdominal pain and bloating have been reported. They can usually be managed by taking the drug with meals or lowering the dose (betahistine SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of acetylsalicylic acid and betahistine need no change. No document names the pair, and acetylsalicylic acid does not belong to the groups of drugs that the betahistine documents link to interactions (SmPCs of both drugs, Spanish Agency of Medicines and Medical Devices, AEMPS). Careful monitoring is recommended during betahistine treatment in people with bronchial asthma or a history of peptic ulcer (betahistine SmPC, AEMPS). Acetylsalicylic acid is contraindicated in asthma and in acute, chronic or recurrent gastric or duodenal ulcer. Its risk of bleeding, ulceration and perforation is higher at higher doses, in older people and in people with a history of gastric ulcer, especially if the ulcer was complicated by bleeding or perforation (acetylsalicylic acid SmPC, AEMPS). Patients are warned about the bleeding risk and its signs: black stools, vomiting blood and marked weakness. If bleeding, ulceration or perforation occurs, acetylsalicylic acid is stopped at once (acetylsalicylic acid SmPC, AEMPS). Acetylsalicylic acid 100 mg gastro-resistant tablets are preferably taken on an empty stomach, at least 1 hour before meals, while betahistine is taken with or after meals (acetylsalicylic acid and betahistine SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Durlaza (aspirin) prescribing information (2015)– FDA, DailyMed setid 4c2a1403-3862-1efd-0a91-444989222b37 (New Haven Pharmaceuticals), revised 09/2015, sections 7
- AEMPS: Ficha técnica: Ácido acetilsalicílico, Adiro 100 mg (nº registro 62825) (2026)– AEMPS, CIMA, nº registro 62825 (Adiro 100 mg comprimidos gastrorresistentes EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Betahistina, Serc 16 mg (nº registro 64130), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 64130 (Serc 8 mg y 16 mg comprimidos, Neuraxpharm Spain), revisión 10/2026, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 5.2